The annual joint scientific meeting of the Singapore Radiological Society and the College of Radiologists, Singapore, was expanded this year to include the Singapore General Hospital nuclear medicine update. This allowed a greater inclusion of topics pertaining to nuclear medicine and radiation oncology, with the theme of the meeting being “imaging and therapy in the area of molecular medicine.”
The 19th Annual Scientific Meeting of the Singapore Radiological Society was jointly organized with the College of Radiologists, Singapore, from Feb. 25 through 28. I have attended this meeting the past three years as it gives me ample opportunity to interact with my colleagues and feel the pulse of radiology in and around the region. Each year, the focus is on a hot topic, and this year’s topic was nuclear medicine and molecular imaging.
It’s not enough that sidelined nuclear reactors are restricting the supply of technetium for cardiac SPECT. Or that reimbursements for SPECT procedures are falling. Now the besieged modality has to contend with a challenge from CT.
Standard nuclear scintigraphy of parathyroid cancer produces enough false positives for patients with multigland disease to lead researchers to recommend rapid intraoperative parathyroid hormone assay along with preoperative technetium-99m sestamibi imaging to assure that all lesions have been removed.
SNM's Clinical Trials Network has expanded to include relationships with European PET radiopharmaceutical manufacturing sites to support molecular and nuclear imaging facilities on the continent that are gearing up to perform scientific studies for the program.